课题基金 / 基金详情

OXIDIZED DNA BASES AS BIOMARKERS OF TUMOR PROGRESSION

OXIDIZED DNA BASES AS BIOMARKERS OF TUMOR PROGRESSION
氧化 DNA 碱基作为肿瘤进展的生物标志物
批准号:
7359010
负责人:
Paul Thomas Henderson
金额:
$8.67万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-01 至 2007-08-31

项目摘要

项目成果

Paul Thomas Henderson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. An early theory of carcinogenesis proposes that DNA is damaged by environmental factors, which lead to changes in the DNA code. These changes are called mutations. Once enough mutations accumulate, cells can no longer function properly, and cancer arises. The facts that smoking causes lung cancer, and that sunlight exposure causes skin cancer support this theory. However, such a direct environmental link is not evident for breast cancer in humans. A more recent theory suggests that the metabolism of oxygen produces free radicals that cause carcinogenic DNA damage. In order to validate the latter theory, it is necessary to measure the products of free radical damage in cells. Damage to cells caused by reactive oxygen is called oxidation. In some breast cancers, increased levels of oxidative DNA damage have been associated with tumor progression. However, the most commonly used marker of DNA oxidation, called 8-oxoG, is known to be chemically unstable, and is difficult to measure accurately. Importantly, 8-oxoG is itself easily oxidized to form several secondary oxidation products. We propose to develop new technology that will allow detection of the products in rat and human breast cancer cells. Such an assay can be used as a foundation for making diagnostics for use in future human clinical and epidemiological studies. An additional benefit of these biomarkers will be their eventual application to chemoprevention in animals and humans. AMS is a desirable technique due to its sensitivity and robustness as a method for high-throughput measurement. In comparison, less quantitative MS methods such as FT-MS lack the precision of AMS for routine operations, especially at the expected level of a few DNA adducts per cell. The combination of these two techniques will allow for the fractionation and detection of protein polypeptides at or below attomole levels, which is necessary for small forensic samples. This project is complementary aims to those of Project 3 of the AMS RR grant, particularly with regard to the use of AMS to further understand cancer etiology using DNA-based markers. Progress to date has been presented in the Research Highlights section of the 2006 APR.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ninja Theranostics for overcoming the drug delivery barriers to pediatric brain tumor
  • 批准号:
    9681305
  • 项目类别:
  • 资助金额:
    $22.5万
  • 财政年份:
    2018
  • 负责人:
    Paul Thomas Henderson
  • 依托单位:
Phase 0 carboplatin microdosing diagnostics trial
DEVELOP ASSAY TO QUANT PLAT-DNA ADDUCTS & PREDICT RESPONSE TO CHEMOTHERA
OXIDIZED DNA BASES AS BIOMARKERS OF TUMOR PROGRESSION
国内基金
海外基金
PCV2茎环结构DNA激活cGAS-STING通路诱导的天然免疫应答的作用研究
  • 批准号:
    2026JJ50413
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    王东亮
  • 依托单位:
机械力响应型DNA探针用于肿瘤微环境细胞力学可视化与药物筛选研究
  • 批准号:
    2026JJ60135
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    杨思慧
  • 依托单位:
CDC45通过调控DNA复制应激促进肝癌发生发展的机制
自供能传感阵列同步量化游离DNA与PSA实现前列腺癌的诊断和预后判断
  • 批准号:
    JCZRLH202601177
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位: